ArticleScientific reports2026
Cost-effectiveness analysis of toripalimab and bevacizumab versus sorafenib for advanced hepatocellular carcinoma in China.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study was to evaluate the cost-effectiveness of toripalimab with bevacizumab compared to sorafenib for advanced hepatocellular carcinoma (HCC) from the Chinese healthcare system perspective. To assess the cost and health outcomes of first-line advanced HCC therapy, we used a partitioned survival model.The model clinical dates were base on the Phase III HEPATORCH trials.The costs considered in this analysis such as drug costs, subsequent therapy cost, and the management of adverse events cost.Quality-adjusted life years (QALY) were used to measure health outcomes and the main economic assessment parameter was the incremental cost-effectiveness ratio (ICER).The willing to pay (WTP) level was 41,876.05 USD per QALY.The robustness and reliability of the model were evaluated using sensitivity analysis. The total cost of toripalimab plus bevacizumab treatment were 45,516.45 USD, while the sorafenib incurred costs of 24,579.02 USD. In compared to sorafenib, the toripalimab plus bevacizumab group achieved an additional 1.35 QALYs and an additional cost of 120,937.43 USD. The ICER was 15,509.21 USD per QALY for the toripalimab plus bevacizumab.One-way sensitivity analysis showed that our results were not reversed when the input paramete fluctuated ± 25%.Toripalimab plus bevacizumab had a 99% chance of being cost-effective at the WTP level. The therapy of toripalimab and bevacizumab was found to be a cost-effective treatment option for patients with advanced HCC in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.